UPDATED: ASCO Abstracts Reveal Added Appeal for Key Cancer Drug Prospects

UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects

Filed under: D.C.

That's the real potential value of tivozanib," Dr. Michael Atkins, a TIVO-1 study investigator and deputy director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, tells FierceBiotech Executive Editor Ryan McBride.
Read more on FierceBiotech


FDA OKs Continued Trials for Potential Pain Drug Class

Filed under: Drug Rehab Centers Washington D.C.

by Victoria Stern Despite a rocky past, it looks like the investigational anti-nerve growth factor (anti-NGF) drug class will continue to be developed to treat pain. In March, an FDA advisory committee voted unanimously (21-0) to move forward with …
Read more on Pain Medicine News


Leave a Reply

Your email address will not be published. Required fields are marked *